BioSpace News Archive

New research from the National Institutes of Health found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease and eye disease.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system.

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that the Company held its Annual General Meeting per Swiss law.

Aeglea BioTherapeutics, Inc. announced that, in connection with the acquisition of Spyre Therapeutics, Inc., a majority of the independent members of Aeglea’s Board of Directors approved the grant of stock options to new employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented data on all patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs).

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral neuropathic pain, or DPNP.

Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced data from its Phase 1b trial for INV-202 to be presented in a poster session at the 83rd American Diabetes Association Scientific Sessions (ADA) in San Diego.

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced it will be added to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.

scPharmaceuticals Inc. today announced that it expects to be added to the small cap Russell 2000 ® and broad market Russell 3000 ® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.

Regulus Therapeutics Inc. today announced Preston S. Klassen , M.D., President and Head of Research & Development, has been appointed to the Company’s Board of Directors.